Drug susceptibility testing of Mycobacterium tuberculosis: A neglected problem at the turn of the century

International Journal of Tuberculosis and Lung Disease

Volumn 3, Issue 7, 1999, Pages 564-581

  Heifets, Leonid ^a   Cangelosi, G A ^b  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^b SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

Author keywords

Drug susceptibility; M. tuberculosis; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ANALYTIC METHOD; DRUG SENSITIVITY; GENETIC HETEROGENEITY; HUMAN; MOLECULAR GENETICS; MYCOBACTERIUM TUBERCULOSIS; PATIENT CARE; PRIORITY JOURNAL; RELIABILITY; REVIEW; SPUTUM SMEAR; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; DRUG RESISTANCE, MULTIPLE; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; SENSITIVITY AND SPECIFICITY; THAILAND; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 0032771444     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (127)

1. Canetti G, Froman S, Grosset J, et al. Mycobacteria: laboratory methods for testing drug sensitivity and resistance. Bull World Health Organ 1963; 29: 565-578.
2. Canetti G, Fox W, Khomenko A, et al. Advances in techniques of testing mycobacterial drug sensitivity and the use of sensitivity tests in tuberculosis control programs. Bull World Health Organ 1969; 41: 21-43.
3. Hong Kong Tuberculosis Treatment Services and British Medical Research Council Investigation. A study in Hong Kong to evaluate the role of pretreatment susceptibility tests in the selection of regimens of chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis 1972; 106: 1-22.
4. Hong Kong Tuberculosis Treatment Services and British Medical Research Council Investigations. A study in Hong Kong to evaluate the role of pretreatment susceptibility tests in the selection of regimens of chemotherapy for pulmonary tuberculosis. Second Report. Tubercle 1974; 55: 169-192.
5. Mitchison D A. Implications of the Hong Kong study on policies of sensitivity testing. Bull Int Union Tuberc 1972; 47: 9-14 (XXIst Intern. Tuberc. Conf. in Moscow, 1971).
6. Fox W. General considerations in the choice and management of regimens of chemotherapy for pulmonary tuberculosis. Bull Int Union Tuberc 1972; 47: 49-67.
7. Gangadharam P R J. Drug resistance in mycobacteria. Boca Raton, FL: CRC Press, 1984: page 119.
8. ATS Position Paper. Drug susceptibility testing for mycobacteria. ATS News, Winter 1984: 9.
9. Coates A R M, Mitchison D A. The role of sensitivity tests in short course chemotherapy. Bull Int Union Tuberc 1983; 58: 110-114.
10. Mitchison D A, Nunn A J. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 1986; 133: 423-430.
11. Ridzon R, Whitney C G, McKenna M T, et al. Risk factors for rifampin mono-resistance. Am J Respir Crit Care Med 1998; 157: 1881-1884.
12. Farmer P, Bayona J, Becerra M, et al. The dilemma of MDR-TB in the global era. Int J Tuberc Lung Dis 1998; 2: 869-876.
13. Faruqi A R, Iseman M D, Hamedani P, et al. Efficacy and safety of rifapentine combination therapy compared with standard therapy in the treatment of pulmonary tuberculosis. Presentation to the Food and Drug Administration. Public hearing, May 5, 1998, Rockville, Maryland.
14. Ellard G A, Mitchison D A. The differing roles of isoniazid and rifampicin in short-course treatment. Int J Tuberc Lung Dis (Abstract Book - 29th World Conference of the IUATLD) 1998; 2 (Suppl 2): S177.
15. Manalo F, Tan F, Sbarbaro J A, Iseman M D. Community-based short-course treatment of pulmonarly tuberculosis in a developing nation. Initial report of an eight-month, largely intermittent regimen in a population with a high prevalence of drug resistance. Am Rev Respir Dis 1990; 146: 1301-1305.
16. Park S K, Kim C T, Song S D. Outcome of chemotherapy in 107 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. Int J Tuberc Lung Dis 1998; 2: 877-884.
17. O'Brien R J. Drug-resistant tuberculosis: etiology, management and prevention. Semin Respir Infect 1994; 9: 104-112.
18. American Thoracic Society. Diagnostic standards and classification of tuberculosis. Am Rev Respir Med 1990; 142 (Suppl): 725-735.
19. Centers for Disease Control. Primary resistance to antituberculosis drugs. Morbid Mort Wkly Rep 1983; 32: 521-523.
20. Bellin E. Failure of tuberculosis control. A prescription for change [Editorial]. JAMA 1994; 271: 708-709.
21. Frieden T, Sterling T, Pablos-Mendez A, Kilburn J O, Canten G, Dooley S W. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 1993; 328: 521-526.
22. Mahmoudi A, Iseman M D. Pitfalls in the care of patients with tuberculosis. Common errors and their association with the acquisition of drug resistance. JAMA 1993; 270: 65-68.
23. Centers for Disease Control. Outbreaks of multidrug-resistant tuberculosis. Morbid Mort Weekly Rep 1990; 39: 364-372.
24. Centers for Disease Control and Prevention. Tuberculosis Morbidity in the United States. Morbid Mortal Wkly Rep 1993; 42: 696-704.
25. McCray E, Weinbaum C M, Braden C R, Onorato I D. The epidemiology of tuberculosis in the United States. In: Iseman M D, Huitt G A, eds. Tuberculosis. Clin Chest Med 1997; 18: 99-113.
26. Agerton T B, Valway S E, Onorato I M. The epidemiology and control of tuberculosis in the United States. In: Heifets L, ed. Clinical Mycobacteriology. Sem Respir Crit Care Med New York-Stuttgart: Thieme Medical Publishers, 1997; 18: 431-438.
27. Frieden T R, Fujiwara P I, Washko R M, Hamburg M A. Tuberculosis in New York City - turning the tide. N Engl J Med 1995; 333: 229-233.
28. Tenover F C, Crawford J T, Heubner R E, Geiter L J, Horsburgh C R, Good R C. The resurgence of tuberculosis: Is your laboratory ready? J Clin Microbiol 1993; 31: 767-770.
29. Joint Tuberculosis Committee of the British Thoracic Society. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax 1998; 53: 536-548.
30. Pablos-Mendez A, Raviglione M C, Laszlo A, Binkin N, Rieder H L, Bustreo F. Global surveillance for antituberculosis drug resistance in 1994-1997. N Engl J Med 1998; 338: 1641-1649.
31. World Health Organization. Antituberculosis drug resistance in the world. The WHO/IUATLD Global Project on Antituberculosis drug resistance surveillance in 1994-1997, Geneva, WHO: 1998.
32. World Health Organization. TB Treatment Observer. March 24, 1997.
33. Khomenko A, Médecins sans Frontières. Cited in Reyes H, Coninx R. Pitfalls of tuberculosis programmes in prisons. Br Med J 1997; 315: 1447-1450.
34. Portaels F, Rigouts L, Bastian I. Addressing multidrug-resistant tuberculosis in penitentiary hospitals and in the general population of the former Soviet Union. Int J Tuberc Lung Dis 1999; 3: 582-588.
35. Farmer P. Epidemiology of primary drug resistance around the world. 29th World Conference of the IUATLD, Workshop 'Primary Drug Resistance in Tuberculosis Patients', Bangkok, Thailand, 1998.
36. Riantawan P, Punnotok J, Chaisuksuwan R, Pransujarit V. Resistance of M. tuberculosis to antituberculosis drugs in the central region of Thailand, 1996. Int J Tuberc Lung Dis 1998; 2: 616-620.
37. Krunner A, Sillast H, Danilov tch M, et al. Drug resistant tuberculosis in Estonia. Int J Tuberc Lung Dis 1998; 2: 130-133.
38. Espinal M A, Baez J, Soriano G et al. Drug-resistant tuberculosis in the Dominican Republic: results of a national survey. Int J Tuberc Lung Dis 1998; 2: 490-498.
39. Foulds J, O'Brien R. New tools of the diagnosis of tuberculosis: the perspective of developing countries. Int J Tuberc Lung Dis 1998; 2: 778-783.
40. Glynn J R, Jenkins P A, Fine P E, et al. Pattern of initial and acquired antituberculosis drug resistance in Karonga district, Malawi. Lancet 1995; 345: 907-910.
41. Sudre R, Cohn D L. Mycobacterium tuberculosis drug resistance: a call to action. Int J Tuberc Lung Dis 1998; 2: 609-611.
42. Iseman M D. MDR-TB and the developing world - a problem no longer to be ignored: the WHO announces 'DOTS Plus' strategy [Editorial]. Int J Tuberc Lung Dis 1998; 2: 867.
43. Laszlo A. Tuberculosis bacteriology laboratory services and incremental protocols for developing countries. In: Heifets L B, ed. Clinical Mycobacteriology. Clin Lab Med Philadelphia: W B Saunders, 1996; 16: 697-716.
44. Iseman M D. Leap-frogging technology into the next century: better diagnostic tests for TB [Editorial]. Int J Tuberc Lung Dis 1998; 2: 777.
45. Telenti A. Genetics of drug resistance in tuberculosis. In: Iseman M D, Huitt G A, eds. Tuberculosis. Clin Chest Med Philadelphia: WB Saunders 1997; 18: 55-64.
46. Heifets L B. The mycobacteriology laboratory: past, present, and future. In: Heifets L B, ed. Clinical Mycobacteriology. Clin Lab Med Philadelphia: WB Saunders, 1996; 16: 513-526.
47. Heifets L B. Drug susceptibility tests in the management of chemotherapy of tuberculosis (Chapter 3). In: Heifets L B, ed. Drug susceptibility in the chemotherapy of mycobacterial infections. Boca Raton, FL: CRC Press, 1991: 89-121.
48. Heifets L. Drug susceptibility testing in mycobacteriology. In: Heifets L B, ed. Clinical Mycobacteriology. Clin Lab Med Philadelphia: WB Saunders, 1996; 16: 641-656.
49. Mitchison D A. What is drug resistance? Tubercle 1969; 50 (Suppl): 44-47.
50. Mitchison D A. Standardization of sensitivity tests [letter]. Int J Tuberc Lung Dis 1998; 2: 69.
51. Laszlo A. Standardization of sensitivity tests [letter in reply]. Int J Tuberc Lung Dis 1998; 2: 70.
52. Kent P T, Kubica G P. Public Health Mycobacteriology. A guide for the Level III Laboratory. Atlanta, GA: CDC, 1985.
53. Vestal A L. Procedures of the isolation and identification of mycobacteria. US Department of Health, Education and Welfare. No77:8320-115, Atlanta, GA: CDC, 1977.
54. David H L. Fundamentals of drug susceptibility testing in tuberculosis. Atlanta, GA, CDC, No. 00-2165, 1971.
55. McClatchy J K. Susceptibility testing of mycobacteria. Lab Med 1978; 9: 47-52.
56. Wayne L G, Krasnow I. Preparation of tuberculosis susceptibility testing medium by means of impregnated discs. Am J Clin Pathol 1966; 45: 769-771.
57. Griffith D E, Barrett H L, Bodily H L, Wood R M. Drug susceptibility tests for tuberculosis using drug impregnated discs. Am J Clin Pathol 1967; 47: 812-817.
58. Laszlo A, Rahman M, Raviglione M, Bustreo F, WHO/ IUATLD Network of Supranational Reference Laboratories. Quality assurance programme for drug susceptibility testing of Mycobacterium tuberculosis in the WHO/IUATLD Supranational Laboratory Network: first round of proficiency testing. Int J Tuberc Lung Dis 1997; 1: 231-238.
59. Welch D F, Guruswamy A P, Sides S J, Shaw C H, Gilchrist M J R. Timely culture for mycobacteria which utilizes a microcolony method. J Clin Microbiol 1993; 31: 2178-2184.
60. Wanger A, Mills K. E-test for susceptibility testing of Mycobacterium tuberculosis and Mycobacterium avium-intracellulare. Diagn Microbiol Infect Dis 1994; 19: 179-181.
61. Wanger A, Mills K. Testing of Mycobacterium tuberculosis susceptibility to ethambutol, isoniazid, rifampin, and streptomycin by using E-test. J Clin Microbiol 1996; 34: 1672-1676.
62. Hausdorfer J, Sompek E, Allerberger F, Dierich M P, Rüsch-Gerdes S. E-test for susceptibility testing of Mycobacterium tuberculosis. Int J Tuberc Lung Dis 1998; 2: 751-755.
63. Roberts G, Goodman N L, Heifets L, et al. Evaluation of the BACTEC radiometric method for recovery of mycobacteria and drug susceptibility testing of M. tuberculosis from acid-fast smear-positive specimens. J Clin Microbiol 1983; 18: 689-696.
64. Siddiqi S H, Libonati J P, Middlebrook G. Evaluation of rapid radiometric method for drug susceptibility testing of M. tuberculosis. J Clin Microbiol 1981; 13: 908-912.
65. National Committee for Clinical Laboratory Standards. Anti-mycobacterial susceptibility testing for M. tuberculosis. Tentative standard M2-T, Villanova, PA: 1995.
66. Heifets L, Sanchez T, Vanderkolk J, Pham V. Development of rifapentine susceptibility tests for Mycobacterium tuberculosis. Antimicrob Agents Chemother 1999; 43: 25-28.
67. Benjamin W H Jr, Waites K B, Beverly A, et al. Comparison of the MB/BacT system with a revised antibiotic supplement kit to the BACTEC 460 system for detection of mycobacteria in clinical specimens. J Clin Microbiol 1998; 36: 3234-3238.
68. Heifets L, Lindholm-Levy P, Gomelsky L, Sanchez T, Brennan J. Drug susceptibility tests for M. tuberculosis. Symposium 'Diagnostic Mycobacteriology', 8th European Congress of Clinical Microbiology and Infectious Disease. Lausanne, Switzerland. May 27, 1997.
69. Heifets L. Choices and dilemmas in drug susceptibility testing of M. tuberculosis isolates. In: Casal M, ed. Clinical Mycobacteriology. Barcelona, Philadelphia: Prous Science, 1998: 259-265.
70. Woods G L, Fish G, Plaunt M, Murphy T. Clinical evaluation of Difco ESP culture system II for growth and detection of mycobacteria. J Clin Microbiol 1997; 35: 121-124.
71. Bergmann J S, Woods G L. Evaluation of the ESP culture system II for testing susceptibilities of Mycobacterium tuberculosis isolates to four primary antituberculous drugs. J Clin Microbiol 1998; 36: 2940-2943.
72. Reisner B S, Gatson A M, Woods G L. Evaluation of mycobacteria growth indicator tubes for susceptibility testing of Mycobacterium tuberculosis to isoniazid and rifampin. Diagn Microbiol Infect Dis 1995; 22: 325-329.
73. Palaci M, Ueki S Y, Sato D N, Da Silva Telles M A, Curcio M, Silva E A. Evaluation of mycobacteria growth indicator tube for recovery and drug susceptibility testing of Mycobacterium tuberculosis isolates from respiratory specimens. J Clin Microbiol 1996; 34: 762-764.
74. Walters S B, Hanna B A. Testing of susceptibility of Mycobacterium tuberculosis to isoniazid and rifampin by mycobacterium growth indicator tube method. J Clin Microbiol 1996; 34: 1565-1567.
75. Suzuki K, Tsuyuguchi K, Matsumoto H, et al. Evaluation of mycobacteria growth indicator tube (MGIT) for drug susceptibility testing of Mycobacterium tuberculosis isolates. Kekkaku 1997; 72: 187-192.
76. Bergmann J S, Woods G L. Reliability of mycobacteria growth indicator tube for testing susceptibility of Mycobacterium tuberculosis to ethambutol and streptomycin. J Clin Microbiol 1997; 35: 3325-3327.
77. Dickinson J M, Allen B W, Mitchison D A. Slide culture sensitivity tests. Tubercle 1989; 70: 115-121.
78. Alcaide F, Telenti A. Molecular techniques in the diagnosis of drug-resistant tuberculosis. Ann Acad Med 1997; 26: 647-650.
79. Drobniewski F A, Wilson S M. The rapid diagnosis of isoniazid and rifampicin resistance in Mycobacterium tuberculosis - a molecular story. J Med Microbiol 1997; 47: 189-196.
80. Rattan A, Dalia A, Ahmad N. Multidrug-resistant Mycobacterium tuberculosis: Molecular perspectives. Emerging Infect Dis 1998; 4: 195-209.
81. Nilsson L E, Hoffner S E, Ansehn S. Rapid susceptibility testing of M. tuberculosis by biolumincscence assay of mycobacteral ATP. Antimicrob Agents Chemother 1988; 32: 1208-1212.
82. Abate G, Mshana R N, Miörner H. Evaluation of a colorimetric assay based on 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) for rapid detection of rifampicin resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis 1998; 2: 1011-1016.
83. Franzblau S G, Witzig R S, McLaughlin J C, et al. Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate alamar blue assay. J Clin Microbiol 1998; 36: 362-366.
84. Yajko D M, Madej J J, Lancaster M V, et al. Colorimetric method for determining MICs of antimicrobial agents for Mycobacterium tuberculosis. J Clin Microbiol 1955; 33: 2324-2327.
85. Norden M A, Kurzynski T A, Bownds S E, Callister S M, Schell R F. Rapid susceptibility testing of Mycobacterium tuberculosis (H37Ra) by flow cytometry. J Clin Microbiol 1995; 33: 1231-1237.
86. Kirk S M, Schell R F, Moore A V, Callister S M, Mazurek G H. Flow cytometric testing of susceptibilities of Mycobacterium tuberculosis isolates to ethambutol, isoniazid, and rifampin in 24 hours. J Clin Microbiol 1998; 36: 1568-1573.
87. Drowart A, Cambiaso C L, Huygen K, et al. Detection of rifampicin and isoniazid resistance of M. tuberculosis by particle counting immunoassay (PACIA). Int J Tuberc Lung Dis 1997; 1: 284-288.
88. Jacobs W Jr, Barletta R, Udani R, et al. Rapid assessment of drug susceptibilities of Mycobacterium tuberculosis by means of lucerifase reporter pliages. Science 1993; 260: 819-822.
89. Riska P F, Jacobs W R, Bloom B R Jr, McKitrick J, Chan J. Specific identification of Mycobacterium tuberculosis with the luceriferase reporter mycobacteriophage: use of p-Nitro-α-Acetylamino-β-Hydroxy propiophenone. J Clin Microbiol 1997; 35: 3225-3231.
90. Carriere C, Riska P F, Zimhony O, et al. Conditionally replicating luciferase reporter pliages: improved sensitivity for rapid detection and assessment of drug susceptibility of Mycobacterium tuberculosis. J Clin Microbiol 1997; 35: 3232-3239.
91. Wilson S, Al-Suwaidi Z, McNerney R, Porter J, Drobniewski F. Evaluation of a new rapid bacteriophage-based method for the drug susceptibility testing of Mycobacterium tuberculosis. Nature Med 1997; 3: 465-468.
92. Kawa D, Pennell D, Kubista L, Schell R. Development of a rapid method for determining the susceptibility of Mycobacterium tuberculosis to isoniazid using the Gen-Probe DNA hybridization system. Antimicrob Agents Chemother 1989; 33: 1000-1005.
93. Koga H, Miyamoto J, Ohno H, Ogawa K, Tomono K, Tashiro T. A rapid drug susceptibility test for Mycobacterium tuberculosis using the hybridization protection assay. J Antimicrob Chemother 1997; 40: 189-194.
94. Martin-Casabona N, Xairo M D, Gonzales T, Rossello J, Arcalis L. Rapid method for testing susceptibility of Mycobacterium tuberculosis by using DNA probes. J Clin Microbiol 1997; 35: 2521-2525.
95. Van der Vliet G M E, Schepers P, Schukkink R A F, van Gemen B, Klatser P R. Assessment of Mycobacterial viability by RNA amplification. Antimicrob Agents Chemother 1994; 38: 1959-1965.
96. Cangelosi G A, Brabant W H, Britschgi T B, Wallis C K. Detection of rifampin- and ciprofloxacin-resistant Mycobacterium tuberculosis by using species-specific assays for precursor rRNA. Antimicrob Agents Chemother 1996; 40: 1790-1795.
97. Cangelosi G A, Brabant W H, Hamlin A M, Haydock P. Molecular probing for mycobacterial nucleic acid synthesis. Abstracts of the National Cooperative Drug Discovery Groups for Treatment of Opportunistic Infections. Annual Meeting, July 27-30, 1998, Bethesda, MD, 1998.
98. Telenti A, Imboden P, Marchesi F, et al. Detection of rifampicin resistant mutations in Mycobacterium tuberculosis. Lancet 1993; 341: 647-650.
99. Badak Z F, Kiska D L, O'Connell M, et al. Confirmation of the presence of Mycobacterium tuberculosis and other mycobacteria in mycobacterial growth indicator tubes (MGIT) by multiplex strand displacement amplification. J Clin Microbiol 1997; 35: 1239-1243.
100. Della-Latta P, Whittier S. Comprehensive evaluation of performance, laboratory application, and clinical usefulness of two direct amplification technologies for the detection of Mycobacterium tuberculosis complex. Am J Clin Pathol 1998; 110: 301-310.
101. Ichiyama S, Ito Y, Sugiura F, et al. Diagnostic value of the strand displacement amplification method compared to those of Roche amplicor PCR and culture for detecting mycobacteria in sputum samples. J Clin Microbiol 1997; 35: 3082-3085.
102. Ieven M, Goossens H. Relevance of nucleic acid amplification techniques for diagnosis of respiratory tract infections in the clinical laboratory. Clin Microbiol 1997; Rev. 10: 242-256.
103. Miller N, Hernandez S G, Cleary T J. Evaluation of GenProbe amplified Mycobacrterium tuberculosis direct test and PCR for direct detection of Mycobacterium tuberculosis in clinical specimens. J Clin Microbiol 1994; 32: 393-397.
104. Service R S. Coming soon: The pocket DNA sequencer. Science 1998; 282: 399-401.
105. Service R S. Microchip arrays put DNA on the spot. Science 1998; 282: 396-399.
106. Burns M A, Johnson B N, Brahmasandra S N, et al. An integrated nanoliter DNA analysis device. Science 1998; 282: 484-487.
107. Heym B, Honoré N, Truffor- Pernot C. Implications of multi-drug resistance for the future of short-course chemotherapy of tuberculosis: A molecular study. Lancet 1994; 344: 293-298.
108. Morris S, Bai G H, Suffys P, Portillo-Gomez L, Fairchok M, Rouse D. Molecular mechanisms multiple drug resistance in clinical isolates of Mycobacterium tuberculosis. J Infect Dis 1995; 171: 9954-9960.
109. Musser J. Antimicrobial agent resistance in Mycobacteria: molecular genetic insights. Clin Microbiol Rev 1995; 8: 496-514.
110. Gingeras T R, Ghandour C, Wang E, et al. Simultaneous genotyping and species identification using hybridization pattern recognition analysis of generic Mycobacterium DNA arrays. Genome Res 1998; 8 435-448.
111. Gamboa F, Cardona P H, Manterola J M. Evaluation of a commercial probe assay for detection of rifampin resistance in Mycobacterium tuberculosis directly from respiratory and nonrespiratory clinical samples. Eur J Clin Microbiol Infect Dis 1998; 17: 189-192.
112. Watterson S A, Wilson S M, Yates M D, Drobniewski F A. Comparison of three molecular assays for rapid detection of rifampin resistance in Mycobacterium tuberculosis. J Clin Microbiol 1998; 36: 1969-1973.
113. Zhang Y, Heym B, Allen B, Young D, Cole S. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 1992; 358: 591-593.
114. Zhang Y, Dhandayuthapani S, Deretic V. Molecular basis for the exquisite sensitivity of Mycobacterium tuberculosis to isoniazid. Proc Natl Acad Sci USA 1996; 93: 13212-13216.
115. Banerjee A, Dubnau E, Quernard A, et al. InhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 1994; 263: 227-230.
116. Mdluli K, Slayden R A, Zhu Y, et al. Inhibition of a Mycobacterium tuberculosis β-ketoacyl ACP synthase by isoniazid. Science 1998; 280: 1607-1610.
117. Meier A, Sander P, Schaper K J, Scholz M, Böttger E C. Correlation of molecular resistance mechanisms and phenotypic resistance levels in streptomycin-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 1996; 40: 2452-2454.
118. Honore N, Cole S T. Streptomycin resistance in mycobacteria. Antimicrob Agents Chemother 1993; 38: 238-242.
119. Xu C B, Kreiswirth N, Sreevatsan S, Musser J M, Drlica K. Fluoroquinolone resistance associated with specific gyrase mutations in clinical isolates of multidrug-resistant Mycobacterium tuberculosis. J Infect Dis 1997; 174: 1127-1130.
120. Scorpio A, Lindholm-Levy P, Heifets L, et al. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 1997; 41: 540-543
121. Telenti A, Philipp W J, Streevatsan S, et al. The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol. Nature Med 1997; 3: 567-570.
122. Cooksey R C, Morlock G P, Glickman S, Crawford J T. Evaluation of a line probe assay kit for characterization of rpoB mutations in rifampin-resistant Mycobacterium tuberculosis isolates from New York City. J Clin Microbiol 1997; 35: 1281-1283.
123. Rossau R, Traore H, De Beenhouwer H, et al. Evaluation of the INNO-LIPA rif. TB assay, a reverse hybridization assay for the simultaneous detection of Mycobacterium tuberculosis complex and its resistance to rifampin. Antimicrob Agents Chemother 1997; 41: 2093-2098.
124. Piatek A, Tyagil S, Pol A C, et al. Molecular beacon sequence analysis for detecting drug resistance in Mycobacterium tuberculosis. Nature Biotechnol 1998; 16: 359-363.
125. Nash K A, Gaytan A, Inderlied C B. Detection of rifampin resistance in Mycobacterium tuberculosis by use of a rapid, simple, and specific RNA/RNA mismatch assay. J Infect Dis 1997; 176: 533-536.
126. Kim B, Kim S, Park K, et al. Mutations in the rpoB gene of Mycobacterium tuberculosis that interfere with PCR-smgle-strand conformation polymorphism analysis for rifampin susceptibility testing. J Clin Microbiol 1997; 35: 492-494.
127. Telenti A, Honore N, Bernasconi C, et al. Genotypic assessment of isoniazid and rifampin resistance in Mycobacterium tuberculosis: a blind study at reference laboratory level. J Clin Microbiol 1997; 35: 719-723.